A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C
A phase 3 trial of Datopotamab deruxtecan, Rilvegostomig, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features is a phase 3 interventional study registered as NCT06564844 by AstraZeneca, with 25 participants enrolled, started 2024-10-15 and due to reach its primary completion in 2027-06-30. Interventions recorded: Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Rilvegostomig, Pemetrexed, Cisplatin, AstraZeneca.
- TrialA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan
Shares Datopotamab deruxtecan, Pemetrexed, Cisplatin, AstraZeneca.
- TrialA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Shares Rilvegostomig, Pemetrexed, Cisplatin, AstraZeneca.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Datopotamab deruxtecan, Pemetrexed, Cisplatin, AstraZeneca.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Pemetrexed, Cisplatin, AstraZeneca, Carboplatin.
- TrialPhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥
Shares Rilvegostomig, Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer.
- TrialDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Shares Datopotamab deruxtecan, Pemetrexed, Cisplatin, Carboplatin.
- TrialA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Shares Rilvegostomig, Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer.